Antineoplastic agent:Hairy cell leukaemia (HCL) Chronic lymphocytic leukaemia (CLL) in patients who have failed to respond to standard regimens
DOSE IN NORMAL RENAL FUNCTION
Leustat:HCL: 0.09 mg/kg (3.6 mg/m 2) daily for 7 daysCLL: 0.12 mg/kg (4.8 mg/m 2) daily for 2 hours on days 1 to 5 of a 28 day cycleLitak:HCL: 0.14 mg/kg/day for 5 days by subcutaneous injectionor according to local protocol
Volume of distribution (L/kg)       :9
half-life – normal/ESRD (hrs)      :3–22/No data
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Use with caution.
10 to 20     : Use with caution
<10           : Use with caution
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
HD                     :Unknown dialysability. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsCaution when administering with any other immunosuppressive or myelosuppressive therapy
ADMINISTRATION
Reconstition
–
Route
SC,
IV infusion
Rate of Administration
24 hours or 2 hours depending on condition being treated
Comments
Add to 100–500 mL of sodium chloride 0.9%
OTHER INFORMATION
Prodrug – activated by intracellular phosphorylation. The nucleotide that is formed accumulates in the cell and is incorporated into the DNA. Regular monitoring is recommended in renal failure Acute renal insufficiency has developed in some patients receiving high-dose . Inadequate data on dosing of patients with renal insufficiency therefore use according to clinical needStudy showed that
<10
% of dose is excreted in urine as metabolites and <20% as parent drug.